297 related articles for article (PubMed ID: 10389994)
1. Radioimmunotherapy of micrometastases in lung with vascular targeted 213Bi.
Kennel SJ; Boll R; Stabin M; Schuller HM; Mirzadeh S
Br J Cancer; 1999 Apr; 80(1-2):175-84. PubMed ID: 10389994
[TBL] [Abstract][Full Text] [Related]
2. Radioimmunotherapy using vascular targeted 213Bi: the role of tumor necrosis factor alpha in the development of pulmonary fibrosis.
Davis IA; Kennel SJ
Clin Cancer Res; 1999 Oct; 5(10 Suppl):3160s-3164s. PubMed ID: 10541358
[TBL] [Abstract][Full Text] [Related]
3. High-linear energy transfer (LET) alpha versus low-LET beta emitters in radioimmunotherapy of solid tumors: therapeutic efficacy and dose-limiting toxicity of 213Bi- versus 90Y-labeled CO17-1A Fab' fragments in a human colonic cancer model.
Behr TM; Béhé M; Stabin MG; Wehrmann E; Apostolidis C; Molinet R; Strutz F; Fayyazi A; Wieland E; Gratz S; Koch L; Goldenberg DM; Becker W
Cancer Res; 1999 Jun; 59(11):2635-43. PubMed ID: 10363986
[TBL] [Abstract][Full Text] [Related]
4. Treatment of lung tumor colonies with 90Y targeted to blood vessels: comparison with the alpha-particle emitter 213Bi.
Kennel SJ; Stabin M; Yoriyaz H; Brechbiel M; Mirzadeh S
Nucl Med Biol; 1999 Jan; 26(1):149-57. PubMed ID: 10096515
[TBL] [Abstract][Full Text] [Related]
5. Vascular targeted radioimmunotherapy with 213Bi--an alpha-particle emitter.
Kennel SJ; Mirzadeh S
Nucl Med Biol; 1998 Apr; 25(3):241-6. PubMed ID: 9620629
[TBL] [Abstract][Full Text] [Related]
6. Therapy of rat tracheal carcinoma IC-12 in SCID mice: vascular targeting with [213Bi]-MAb TES-23.
Kennel SJ; Lankford T; Davern S; Foote L; Taniguchi K; Ohizumi I; Tsutsumi Y; Nakagawa S; Mayumi T; Mirzadeh S
Eur J Cancer; 2002 Jun; 38(9):1278-87. PubMed ID: 12044516
[TBL] [Abstract][Full Text] [Related]
7. Microdosimetric analysis of alpha-particle-emitting targeted radiotherapeutics using histological images.
Akabani G; Kennel SJ; Zalutsky MR
J Nucl Med; 2003 May; 44(5):792-805. PubMed ID: 12732682
[TBL] [Abstract][Full Text] [Related]
8. Combination vascular targeted and tumor targeted radioimmunotherapy.
Kennel SJ; Lankford TK; Foote LJ; Davis IA; Boll RA; Mirzadeh S
Cancer Biother Radiopharm; 1999 Oct; 14(5):371-9. PubMed ID: 10850322
[TBL] [Abstract][Full Text] [Related]
9. Fractionated locoregional low-dose radioimmunotherapy improves survival in a mouse model of diffuse-type gastric cancer using a 213Bi-conjugated monoclonal antibody.
Bloechl S; Beck R; Seidl C; Morgenstern A; Schwaiger M; Senekowitsch-Schmidtke R
Clin Cancer Res; 2005 Oct; 11(19 Pt 2):7070s-7074s. PubMed ID: 16203804
[TBL] [Abstract][Full Text] [Related]
10. 213Bi radioimmunotherapy with an anti-mCD138 monoclonal antibody in a murine model of multiple myeloma.
Chérel M; Gouard S; Gaschet J; Saï-Maurel C; Bruchertseifer F; Morgenstern A; Bourgeois M; Gestin JF; Bodéré FK; Barbet J; Moreau P; Davodeau F
J Nucl Med; 2013 Sep; 54(9):1597-604. PubMed ID: 24003167
[TBL] [Abstract][Full Text] [Related]
11. Therapeutic efficacy and tumor dose estimations in radioimmunotherapy of intraperitoneally growing OVCAR-3 cells in nude mice with (211)At-labeled monoclonal antibody MX35.
Elgqvist J; Andersson H; Bäck T; Hultborn R; Jensen H; Karlsson B; Lindegren S; Palm S; Warnhammar E; Jacobsson L
J Nucl Med; 2005 Nov; 46(11):1907-15. PubMed ID: 16269606
[TBL] [Abstract][Full Text] [Related]
12. Locoregional alpha-radioimmunotherapy of intraperitoneal tumor cell dissemination using a tumor-specific monoclonal antibody.
Huber R; Seidl C; Schmid E; Seidenschwang S; Becker KF; Schuhmacher C; Apostolidis C; Nikula T; Kremmer E; Schwaiger M; Senekowitsch-Schmidtke R
Clin Cancer Res; 2003 Sep; 9(10 Pt 2):3922S-8S. PubMed ID: 14506190
[TBL] [Abstract][Full Text] [Related]
13. Radiotoxicity of bismuth-213 bound to membranes of monolayer and spheroid cultures of tumor cells.
Kennel SJ; Stabin M; Roeske JC; Foote LJ; Lankford PK; Terzaghi-Howe M; Patterson H; Barkenbus J; Popp DM; Boll R; Mirzadeh S
Radiat Res; 1999 Mar; 151(3):244-56. PubMed ID: 10073661
[TBL] [Abstract][Full Text] [Related]
14. Intravesical alpha-radioimmunotherapy with 213Bi-anti-EGFR-mAb defeats human bladder carcinoma in xenografted nude mice.
Pfost B; Seidl C; Autenrieth M; Saur D; Bruchertseifer F; Morgenstern A; Schwaiger M; Senekowitsch-Schmidtke R
J Nucl Med; 2009 Oct; 50(10):1700-8. PubMed ID: 19793735
[TBL] [Abstract][Full Text] [Related]
15. Vascular-targeted radioimmunotherapy with the alpha-particle emitter 211At.
Kennel SJ; Mirzadeh S; Eckelman WC; Waldmann TA; Garmestani K; Yordanov AT; Stabin MG; Brechbiel MW
Radiat Res; 2002 Jun; 157(6):633-41. PubMed ID: 12005541
[TBL] [Abstract][Full Text] [Related]
16. 211At radioimmunotherapy of subcutaneous human ovarian cancer xenografts: evaluation of relative biologic effectiveness of an alpha-emitter in vivo.
Bäck T; Andersson H; Divgi CR; Hultborn R; Jensen H; Lindegren S; Palm S; Jacobsson L
J Nucl Med; 2005 Dec; 46(12):2061-7. PubMed ID: 16330571
[TBL] [Abstract][Full Text] [Related]
17. In vitro targeting of NG2 antigen by 213Bi-9.2.27 alpha-immunoconjugate induces cytotoxicity in human uveal melanoma cells.
Li Y; Wang J; Rizvi SM; Jager MJ; Conway RM; Billson FA; Allen BJ; Madigan MC
Invest Ophthalmol Vis Sci; 2005 Dec; 46(12):4365-71. PubMed ID: 16303921
[TBL] [Abstract][Full Text] [Related]
18. Highly specific tumor binding of a 213Bi-labeled monoclonal antibody against mutant E-cadherin suggests its usefulness for locoregional alpha-radioimmunotherapy of diffuse-type gastric cancer.
Senekowitsch-Schmidtke R; Schuhmacher C; Becker KF; Nikula TK; Seidl C; Becker I; Miederer M; Apostolidis C; Adam C; Huber R; Kremmer E; Fischer K; Schwaiger M
Cancer Res; 2001 Apr; 61(7):2804-8. PubMed ID: 11306447
[TBL] [Abstract][Full Text] [Related]
19. Alpha-emitting bismuth cyclohexylbenzyl DTPA constructs of recombinant humanized anti-CD33 antibodies: pharmacokinetics, bioactivity, toxicity and chemistry.
Nikula TK; McDevitt MR; Finn RD; Wu C; Kozak RW; Garmestani K; Brechbiel MW; Curcio MJ; Pippin CG; Tiffany-Jones L; Geerlings MW; Apostolidis C; Molinet R; Geerlings MW; Gansow OA; Scheinberg DA
J Nucl Med; 1999 Jan; 40(1):166-76. PubMed ID: 9935073
[TBL] [Abstract][Full Text] [Related]
20. Enhanced tumour uptake of radiolabelled antibodies by hyperthermia: Part I: Timing of injection relative to hyperthermia.
Hauck ML; Zalutsky MR
Int J Hyperthermia; 2005 Feb; 21(1):1-11. PubMed ID: 15764347
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
